Physics, makers of diagnostic radiopharmaceuticals and molecular imaging agents. | GE HealthCare plans to take full control ...
Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop: analyst
With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
Cancer-focused Alligator Bioscience is clamping down on costs, laying off 70% of its team in efforts to save around $6 ...
Novocure has cleared a phase 3 clinical study in pancreatic cancer, showing its tumor-treating electric fields could help ...
GE HealthCare has unveiled a new mammography system with artificial intelligence-powered features that it says are aimed at ...
Each year, we assemble our list of marquee names in the Fierce 15—featuring the most innovative private companies and ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75% drop in the biotech’s share price. Applied said the complete response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback